A Randomized Trial of Thymoglobulin to Prevent Chronic ... - CBMTG

More documents

Recommendations

Info

Performance of QPCR test for EBVAssume prevalence of PTLD will be 3%PTLD YESPTLD NOTEST POS 3 60 PPV 3/63= 0.48%TEST NEG 0 40 NPV 40/(40+0)= 100%Sensitivity3/(3+0)= 100%Specificity40/(40+60)= 40%Rising titres adds specificity.Presence of EBV-specific CTL in blood improves specificity (To 100%?)
Shulman/Sullivan cf. NIHShulman/Sullivan• Time dependent ±100 days• Classification– Classic acute 100 days• Only Skin and Liver diagnostic• No patient centred parametersNIH• Manifestation dependent• Classifications:– Classic acute 100days– chronic any time– Overlap syndrome any time• Skin, lung, mouth, genitalia, GI,lungs, soft tissues are diagnostic• Symptoms and function added,description more detailed e.g.extent, ulceration
Page 1 and 2: A Randomized Trial of Thymoglobulin
Page 3 and 4: Appendix AIllustrations of cGVHD -
Page 5: Quality of LifeFraser CJ et al. Imp
Page 12 and 13: A Randomized Trial of Thymoglobulin
Page 14 and 15: FundingTOTAL GRANT:CIHR:$1,245,055
Page 16 and 17: FinkeLancet Oncol 2009;10: 855-64Ba
Page 18 and 19: Time to Onset of Prednisone RxMielk
Page 20 and 21: Secondary End-Points• Time to eng
Page 22 and 23: Treatment Plan - ThymoglobulinThe e
Page 24 and 25: Flu-Bu-ATG (Slavin) vs F-TBI (Seatt
Page 26 and 27: Benefits and Harms• BENEFITS• L
Page 28 and 29: PTLD in Unrelated/Mismatch +ATGStud
Page 32 and 33: cGVHD Manifestions - NIHFilipovich
Page 34 and 35: cGVHD Case Report Form (CRF)
Page 36 and 37: cGVHD Case Report Form (CRF)
Page 38 and 39: Body Surface Area (Rule of 9)
Page 40 and 41: Will CBMTG 0801 succeed?In part for
Page 42 and 43: Flowers ME, Storer BE, Lee SJ, et a
Page 44: Thank you

A Randomized Trial of Thymoglobulin to Prevent Chronic ... - CBMTG

Create successful ePaper yourself

Delete template?

Save as template?